Description
General description
21 kDa
Two families of cyclin dependent kinase inhibitors (CKIs) have been identified. The p21WAF1/Cip1 family inhibits all kinases involved in the G1/S transition. The p16INK4a family inhibits Cdk4 and Cdk6 specifically. The biochemical activities and patterns of expression of CKIs during development implicate these proteins as the primary effectors of signaling pathways that control cell cycle exit, an event that is critical for differentiation. Studies have shown that p21WAF1/Cip1 binds tightly to the G1 and S phase kinases, cyclin E/Cdk2, cyclin D/Cdk4, and cyclin A/Cdk2, and effectively inhibits their activity, whereas p21WAF1/Cip1 is a relatively poor inhibitor of the G2/M phase kinase cyclin B/Cdc2. In addition, p21WAF1/Cip1 inhibits proliferating cell nuclear antigen (PCNA), binds to and inhibits inactivation of Rb, which is essential for cell cycle progression, and may also interact with E2F and protect cells against p53-mediated apoptosis.
Immunogen
Epitope: amino acids 1-80
Recombinant full-length human Cip1 with a histidine tag.
Application
Immunoprecipitation: 4 μg of a previous lot immunoprecipitated Cip1 from 500 μg of HeLa nuclear extract.
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Cell Cycle, DNA Replication & Repair
Use Anti-p21/WAF1/Cip1 Antibody (Mouse Monoclonal Antibody) validated in WB, IP to detect p21/WAF1/Cip1 also known as CDK-interacting protein or cyclin-dependent kinase inhibitor 1A.
Biochem/physiol Actions
Other species cross-reactivity is unknown.
Recognizes Cip1, MW 21 kDa
Physical form
Format: Purified
Protein G Purified
Purified, pooled monoclonal mouse IgGs in buffer containing 0.1 M Trisglycine, pH 7.4, 0.15 M NaCl containing 0.05% sodium azide. Frozen solution.
Preparation Note
Stable for 1 year at from date of receipt.
Analysis Note
Control
Positive Antigen Control: Catalog #12-309, Hela cell nuclear extract. Add an equal volume of Laemmli reducing sample buffer to 10 μL of extract and boil for 5 minutes to reduce the preparation. Load 20 μg of reduced extract per lane for minigels.
Evaluated by western blotting on HeLa nuclear extract.
Western Blot Analysis: 0.5-2 μg/mL of this antibody detected Cip1 in 20 μg of HeLa nuclear extract
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
